anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Atazanavir is an inhibitor of CYP3A and UGT1A1. Coadministration of atazanavir and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.

Atazanavir is a weak inhibitor of CYP2C8. Use of atazanavir without ritonavir is not recommended when coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide). When atazanavir with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected [see Clinical Pharmacology, Table 22 (12.3)].

The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when atazanavir is coadministered with ritonavir. See the complete prescribing information for ritonavir for information on drug interactions with ritonavir.
The present invention pertains to a pharmaceutical dosage from comprising an opioid agonist and one or more opioid antagonists contained in a matrix separate from the opioid agonist.  The separate matrix for the opioid antagonist allows independent release rates to be achieved for the opioid and opioid antagonist(s). The antagonist(s) can be released slowly or fully contained when the tablet is taken orally. Crushing the tablet allows full release of the antagonist(s), deterring abuse. The abuse deterring antagonist(s) may be an opioid antagonist, an irritant, another appropriate antagonist(s), or a combination thereof. The invention also allows variable release of the opioid and antagonist(s).
This invention comprising a single or plural strains of Lactobacillus having special characteristics that have been never known is a new type of pharmaceutical Lactobacillus preparation for the treatment of infectious diseases. Some of the characteristics of Lactobacillus used for the present invention as as follows. (a) They are able to grow in low nutrition. (b) The speed of multiplication is quick. (c) By odoriferous S-, N- & C-compound, is promoted the growth. The effects of the present invention are as follows. Unlike the antibiotics which serves only to kill the bacteria, the present preparation is characteristic in that (a) it is non-pathogenic; (b) it can produce antibiotics thereby killing bacteria; (c) it can survive in the growth competition with pathogenic or other bacteria; (d) it denatures the metabolites (including poisonous ones) of living bodies or convert them into constituents of its own cells; (e) it purifies an affected part; (f) it shows anti-inflammatory or anti-swelling activities; and finally (g), as said preparation is foreign to the living bodies and is non-pathogenic, it is at least digested after the inflammatory diseases disappear. Accordingly, the present invention can be used extensively to give better therapeutic effects, except where the physical structure does not permit to use it.
Completed

55 participants with evidence of the MetS and autonomic neuropathy will be assessed for fall risk with the Four Square Step Test (FSST), which is a measure of dynamic standing balance. Additional endpoints include the dynamic gait index. Measures of height, weight, and waist circumference will be taken and an oral glucose tolerance test as well as lipids and blood pressure will also be measured. Autonomic function will be measured using cardiac autonomic testing, quantitative sudomotor axon reflex test and tilt table testing. Participants will be randomized into either a standard care group that will receive fall risk education or a targeted balance exercise intervention group. Both groups will meet once a week. The intervention group will receive a 12 week balance program with personalized incremental increases in the amount and difficulty of each maneuver.
The present invention provides mammalian retinoblastoma (Rb) protein-interacting zinc finger (RIZ) proteins, nucleic acid molecules encoding the RIZ and antibodies specific for the RIZ. The invention also provides screening assays for identifying an agent that effectively alters the association of a RIZ with a second molecule, which can bind to the RIZ. The invention also provides active fragments of RIZ containing the PR domain, which can regulate transcription. In addition, the invention provides methods for introducing a nucleic acid molecule-encoding a RIZ into a cell and for A-contacting a cell with an effective agent in order to modulate a function of a cell. Such methods are useful, for example, for inducing growth of a cardiac cell or a neuronal cell in a subject and for effecting normal growth control to a tumor cell or causing differentiation of tumor cells. The invention further provides methods for detecting a RIZ in a sample by detecting the RIZ or a nucleic acid molecule encoding the RIZ. Such methods are useful to diagnose a pathology that is characterized by an increased or decreased level of a RIZ in a cell or by expression of a mutant RIZ in a cell.
This study aimed to develop hydrogel dressings for wound healing composed of gum tragacanth (TG) and polyvinyl alcohol (PVA) loaded with Graphene oxide (GO) and Cinnamon oil (CMO) using electron beam irradiation. The impact of the preparation conditions and the incorporation of GO and CMO on the characteristic properties of the prepared CMO-(PVA/TG)-GO wound dressings was evaluated. The healing-related characteristics were assessed, including fluid absorption and retention, water vapor transmission rate (WVTR), hemolytic assay, and antimicrobial potential. Wound healing efficacy was evaluated using a scratch wound healing assay. FTIR analysis verified the chemical structure, whereas scanning electron microscopy demonstrated an appropriate porosity structure necessary for optimal wound healing. The gel content increases with the initial total polymer concentration and the irradiation dose increases. Higher GO and CMO content improve the gel content and decreases swelling. WVTR decreases with the rise in CMO content. In vitro, cytotoxicity and hemolytic potency assessments confirmed their biocompatibility. The incorporation of GO and CMO enhances the antimicrobial activity and wound-healing capability. Based on the above findings, CMO-(PVA/TG)-GO dressings show promising potential as candidates for wound care.
A medical device includes a QR generator and a user access/activity log. The QR generator generates a QR code at least from a username of a user and at least one OTP (one-time password) for the user and enables access of the user to the medical device upon receiving an OTP from the user. The user sends the QR code to an online authorization server for the medical device for decryption upon authentication of the user. The log lists user activity once the user is authenticated by the server. The server receives the QR code, which includes at least an encrypted text containing at least the OTP and a user identification, and decrypts the encrypted text using a private key associated with the medical device. The authorization server enables the user to log in for authentication and, if authenticated, displays the at least one OTP to the user.
1503444 Topical compositions MINNESOTA MINING & MFG CO 23 March 1976 [24 March 1975] 11672/76 Heading A5B Non-greasy occulusive compositions for topical application to the skin as cosmetics or ointment bases comprise 40 to 90% by weight of a viscous base comprising solid petroleum, animal oils, mineral oils and/or synthetic oils, in which the oils have been thickened with wax and/or a hydrocarbon polymer, and 10 to 60% by weight of an ointment forming powder which is non-irritating to human skin, solid at 25C, insoluble in water and the other components of the composition, has a number average dimension of less than 30 microns and is substantially non-absorbent to the viscous base at temperatures below 50C, the ointment forming powder having been mixed with the viscous base at a temperature of less than 50C. The ointment forming powder may be a polyolefin such as polyethylene, hydrated magnesium silicate or hydrated aluminium silicate. The thickening agent may be a polyolefin e.g. polyethylene or cholesterol. The composition may also contain a styrene copolymer and/or a consistency modifier. The composition may be in the form of an ointment; lotion or cream. The composition may contain a medicament such as a corticosteroid e.g. dexamethasonet-butyl acetate, bacitracin, neomycin sulphate or polymyxin B sulphate.
Further study details as provided by Hanyang University Hospital

This study is prospective study of newly diagnosed LTBI in HCWs at Hanyang University Hospital, a tertiary referral hospital in South Korea, between 2017 and 2018. This study aimed to identify the prevalence of adverse reactions of treatment regimen for LTBI. The diagnosis of LTBI was made on the basis of interferon-gamma releasing assay. Information on demographic characteristics, comorbidity and treatment outcomes was collated from questionnaires. Treatment regimen for LTBI was chosen by patients' preference among 3 months of INH(isoniazid) plus RFP(rifampin), 4 months of RFP and 9 months of INH. All PTB patients were observed 2 weeks after the initiation of medication, and monthly thereafter, and were asked about any drug side effects at these visits. Serious adverse drug reaction (ADR) was defined as any severe side effect that resulted in discontinuation or change (either temporally or permanently) of anti-TB medication, and/or directly resulted in hospitalization. Drug-induced hepatitis was defined as liver transaminases more than three times higher than the upper limit of normal in the presence of symptoms such as anorexia, nausea, vomiting, or abdominal pain, or transaminases more than five times the upper limit of normal without symptoms.
COPD and asthma are two of the most common chronic lung diseases, affecting over 545 million people globally and 34 million in the United States. Annual health care costs related to chronic lung disease are estimated at €380 billion in the European Union, and $24-$50 billion in the United States averaging to $4,000 in out-of-pocket costs per person in the U.S. A full-text literature search was conducted for English publications between January 1, 2005-March 18, 2024. It returned over 5,000 publications that were further narrowed using key search words, resulting in 172 peer-reviewed articles. Using their experience and subject expertise, the authors further narrowed the peer-reviewed articles to 55 that were in their opinion relevant. Also, 38 recently published industry reports and news articles specific to downstream effects of inhaler market changes and the future impact were included. The literature suggests that individuals with chronic lung disease face increased challenges with access to inhaled medication due to rising medication costs, discontinuation of branded medications, introduction of generic medications not covered by insurance, exclusionary preferred drug list tactics that force health care providers into non-medical switching of medication or devices, and ongoing medication shortages. Providers experience ongoing hurdles in prescribing appropriate inhaled medications for individuals with chronic lung disease, including increased time and costs spent on administrative tasks due to inhaler denials, a loss of patient trust, and limits on their ability to prescribe appropriate inhaled medication for individuals with chronic lung disease.
Under classical conditions, protein a chromatography columns are generally less effective in removing antibody aggregates. The invention provides a combination and method that can significantly improve the aggregate removal capacity of a protein a chromatographic column. The combination comprises polyethylene glycol (PEG) and a salt (chaotropic or kosmotropic) as additives in the wash buffer and the elution buffer. The synergistic effect of the salt and PEG results in almost complete separation of the monomers from the aggregates. In the example used for demonstration, the optimization procedure reduced aggregates in the elution pool from 20% to 3-4% compared to the control. This new method improves the overall robustness of the downstream process by facilitating the removal of aggregates at the capture step.
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.
Adults attempting weight loss through lifestyle modification (LM) typically find maintenance of behavior change difficult. Outcomes might be improved if participants are provided with sustained sources of accountability and support and ongoing opportunities to reflect with others on goal progress. This study proposes that sharing digital data with other parties has the potential to improve long-term weight loss. The proposed study will enroll adults ("index participants") (N = 320) with overweight/obesity in a 24-month LM program and instruct them to use digital tools for self-monitoring of weight, physical activity, and eating on a daily basis. Groups will meet remotely each week in months 1-3 to initiate weight loss. In months 4-24, intervention contact will be remote and will include the following: quarterly group meetings held via videoconference; brief phone calls with the coach held twice per quarter; and monthly text messages with the coach, with a small group of fellow group participants, and with a friend or family member outside of the program. Text message content will vary according to treatment condition, i.e. three types of data sharing partnerships: Coach Share, Group Share, and Friend/Family Share. Outcomes will be measured at months 0, 3, 6, 12, and 24. Primary aims include determining if Coach Share, Group Share, and Friend/ Family Share each improve long-term weight loss, PA, and calorie intake, and examining if effects are additive when participants are assigned to engage in more than one type of data sharing partnership. The secondary aim is to explore mediators and moderators of intervention effects. The tertiary aim is to determine how the quality of relationship with coach, group members, and friends/family member over time may differentially moderate treatment effects and predict data sharing efficacy. As digital technology makes data sharing increasingly feasible, it is critical to determine how to optimize these partnerships to improve long-term outcomes in LM.
The invention relates to a traditional Chinese medicine pill for expelling the stasis of qi and regulating the flow of qi, which comprises the following components in parts by weight: 2-3 parts of immature bitter orange, 1-2 parts of green tangerine peel, 1-2 parts of tangerine peel, 2-3 parts of rosa banksiae, 2-3 parts of fructus citri sarcodactylis, 3-4 parts of rose, 2-3 parts of Prunus mume (Sieb.) Sieb.et Zucc, a right amount of honey and sesame oil. The traditional Chinese medicine pill is prepared by the following steps: pulverizing the immature bitter orange, the green tangerine peel, the tangerine peel, the rosa banksiae, the fructus citri sarcodactylis, the rose and the Prunus mume (Sieb.) Sieb.et Zucc by a physical method, sieving by a sieve of 400 meshes, then blending by a right amount of honey and sesame oil, and preparing a pill. The invention has unique formula, high cure rate, no side effect, simple and convenient application, simple preparation method and low production cost, has very good curative effect to the symptom of the stasis of qi caused by various reasons and is the traditional Chinese medicine pill. Clinically, the invention has obvious effect when being used for treating various symptoms caused by the stasis of qi.
The invention relates to the technical field of foods and drinks, in particular to a Chinese wolfberry wine and a preparation method thereof. The invention aims to provide a drinkable wine prepared from Chinese wolfberry and flower of kudzuvine serving as main raw materials. After the drinkable wine is drunk by a person, the drinkable wine can achieve the effect of diluting alcohol, and also has the effects of invigorating qi and strengthening the spleen, and nourishing the blood and tranquilizing mind. The wine comprises the following components: 10 to 20g of Chinese wolfberry, 6 to 17g of flower of kudzuvine, 7 to 18g of Chinese date and 500ml of 52-degree white spirit. One of the components, namely the flower of kudzuvine is prepared into a solution by a boiling method, and when the solution is added into a wine, isoflavone in the flower of kudzuvine can quickly decompose ethanol to achieve the effect of relieving alcoholism; meanwhile, the Chinese wolfberry has the effects of reducing cholesterol and resisting fatigue; and the Chinese date has the effects of invigorating qi and strengthening the spleen, and nourishing the blood and tranquilizing mind. The wine is not added with components such as essences, preservatives and the like, and is suitable to be drunk for a long term.
Patients participate in Enhancing Connections Program comprising of anchoring patients to help their child, adding to listening skills, building on listening skills, being a detective of their child's coping, and celebrating success for 5 sessions. Patients also receive workbook which includes text from the sessions, handouts, and at-home assignments to be completed between sessions.
There is evidence that the magnitude of the placebo effect produced by a device is greater than that produced by a pill. If this is the case, it has significant ramifications for all trials involving devices and for our understanding of the role of the placebo effect in randomized controlled trials (RCT). This two phase study 1)investigates the role of the placebo effect in RCT's and 2)conducts two trials of treatments for persistent upper extremity pain secondary to repetitive strain injury (RSI), including carpel tunnel syndrome. In Phase I. 240 patients with RSI are randomly assigned to receive a placebo device (a recently validated sham acupuncture device) or a placebo pill (dummy amitriptyline). Our primary hypothesis is that patients will respond better to the sham device than the placebo pill. A finding that sham acupuncture produces a greater placebo response than a placebo pill has important implications for the interpretation of results in trials that compare devices to sham devices, devices to pills, and medical management to surgery. Phase II randomly assigns patients from the sham acupuncture arm of Phase I to receive either TCA or continue to receive the sham version. Patients in the placebo pill arm of Phase I will be randomly assigned to receive either AMI or continue receiving the placebo pill. From the patients'perspective, the shift in treatment assignment from Phase I to II should not be noticeable. Phase II will allow us to test whether the active treatments outperform their respective placebos. Both of these treatments have shown promise in small studies, but neither has been prospectively studied in a large trial with appropriate controls. Because Phase I also functions as a run-in period for Phase II, analysis combining both phases will allow us to examine whether a run-in has methodological advantages in a device trial. Moreover, combined analyses permit testing whether patients level of response to placebo in Phase I affects their response to active treatment Phase II. A positive finding here would contribute importantly to our understanding of the role of the placebo in RCTs.
Women who use drugs during pregnancy place their unborn children at high risk for being born addicted to drugs. Such children may also be born with birth defects and may experience learning and behavioral problems. Methadone, a synthetic narcotic, is commonly prescribed to treat opioid addiction. It may not be an optimal solution for opioid-dependent pregnant women, however, because a large percentage of children born to women taking methadone experience severe drug withdrawal symptoms at birth that often require medical treatment. Common opioid withdrawal symptoms, described as neonatal abstinence syndrome (NAS) in babies, include tremors, irritability, sleep problems, seizures, dehydration, and fever. Buprenorphine is a medication that has been approved to treat opioid dependence in individuals who are not pregnant but has not been approved for pregnant individuals. Past research has shown that use of buprenorphine in pregnant women results in improved birth outcomes over methadone. The purpose of this study is to evaluate the effectiveness of buprenorphine versus methadone at reducing opioid withdrawal symptoms in babies born to opioid-dependent women.

This study will enroll opioid-dependent pregnant women who are 13 to 30 weeks pregnant and will follow each woman and her child throughout the pregnancy until 6 weeks postpartum. All participants will undergo an initial screening that will last several hours. Participants will then be randomly assigned to receive either methadone or buprenorphine on a daily basis, and will be required to visit the clinic each day to receive their medication. Outcome measurements will be assessed at weekly study visits throughout the pregnancy, and will include drug use, HIV risk behaviors, medication dose adequacy and safety, treatment retention, and psychosocial functioning. Urine samples will be collected 3 times a week, and blood will be drawn throughout the pregnancy for safety monitoring. Outcome measurements related to the baby will include head circumference measurement, length of hospital stay, severity and frequency of withdrawal symptoms, and amount of medication needed to control withdrawal symptoms.
A user-interactive computer program provides drug advice. Drugs are grouped according to their clinical and chemical characteristics in a supporting data base. For each drug, a drug database contains detailed information on pharmacokinetics, pharmaco-dynamics and drug-specific details. In response to user interaction with areas displayed on the screen, the computer program obtains pertinent drug interaction information from the database. With the obtained information, the computer program supports display of graphical screen views. Contents of the screen views include symbols for indicating respective drugs, geometrically distinguishing lines for indicating interaction between drugs, and text descriptions of drug information. Further included in the screen views are respective symbols for indicating drug warnings for pregnant or lactating women and sportspersons. Color coding may also be employed in the screen views to indicate degree of effect or warning.